The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 16 rounds in the feed, most often at Series B and in Biotech.
We fuel the success of emerging biotechnology companies worldwide by identifying transformative cancer medicines.
Venture capitalZurich, Switzerlandnextechinvest.comRounds from 2020-03-17 to 2026-10-23
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Hexagon Bio A biopharmaceutical company pioneering the discovery of novel payload mechanisms for antibody-drug conjugates (ADCs) | Series C Verified against 4 of 14 sources | $62M | 2026-10-23 | [ PART ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series E |
| $92.5M |
| 2026-09-16 |
| [ PART ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series C Verified against 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $85M | 2026-06-30 | [ LEAD ] |
Stipple Bio Stipple Bio develops targeted oncology therapies through precision mapping of tumor-specific epitopes for cancer treatment. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-04-06 | [ LEAD ] |
Atavistik Bio Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT). | Series B ext. Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2026-03-05 | [ PART ] |
Atavistik Bio Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT). | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-12-18 | [ LEAD ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $358.0M | 2025-10-15 | [ PART ] |
Airna AIRNA develops RNA editing therapeutics aimed at delivering functional cures for patients with rare diseases and common conditions. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $155M | ~ 2025-04 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $139.8M | 2024-03-14 | [ LEAD ] |
Atavistik Bio Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT). | Funding round Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2023-12-19 | [ PART ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $123M | 2023-03-22 | [ PART ] |
Hexagon Bio A biopharmaceutical company pioneering the discovery of novel payload mechanisms for antibody-drug conjugates (ADCs) | Funding round Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $61M | 2021-09-22 | [ LEAD ] |
Atavistik Bio Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT). | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2021-08-24 | [ PART ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series C Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $66M | 2021-06-16 | [ LEAD ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $82M | 2021-05-13 | [ PART ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $45M | 2020-03-17 | [ PART ] |